Will a patient taking bupropion (Wellbutrin) 450mg/day test positive for amphetamines on a urine test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bupropion and False-Positive Amphetamine Urine Drug Screens

Yes, bupropion at 450mg/day can cause false-positive amphetamine urine drug screens, and this is a well-documented phenomenon that occurs frequently with immunoassay-based testing. 1

Mechanism and Frequency

The FDA drug label explicitly warns that bupropion can cause false-positive urine test results for amphetamines, listing this as a documented drug-laboratory test interaction. 1 This is not a rare occurrence—research demonstrates that therapeutic use of bupropion is actually the most frequent cause of false-positive amphetamine screens in clinical populations. 2

In a large retrospective study of over 10,000 urine drug screens, among 128 samples that screened positive for amphetamines but failed to confirm on gas chromatography, 41% (53 patients) were taking bupropion—making it by far the leading cause of false-positives. 2 Notably, none of these patients with bupropion-related false-positives had evidence of polysubstance abuse, suggesting the medication itself was responsible. 2

Dose-Dependent Considerations

The false-positive reaction appears to be concentration-dependent. Research shows that bupropion metabolites can trigger positive amphetamine screens when present at concentrations greater than 500 ng/mL in certain immunoassay kits. 3 At your patient's dose of 450mg/day (the maximum recommended dose), metabolite concentrations would likely exceed this threshold, making false-positive results highly probable. 1, 3

Test-Specific Variability

Not all immunoassay tests are equally susceptible to this cross-reactivity. Studies demonstrate that two specific enzyme-linked immunosorbent assay (ELISA) kits—particularly the Amphetamine ULTRA kit—are prone to false-positives with bupropion metabolites. 3 The Syva EMIT II immunoassay, commonly used in emergency departments and clinical settings, also shows significant cross-reactivity. 2

Clinical Management Algorithm

When interpreting a positive amphetamine screen in a patient taking bupropion:

  1. Assume the result is false-positive until proven otherwise, especially if there is no clinical evidence of amphetamine use or polysubstance abuse. 2

  2. Order confirmatory testing with gas chromatography-mass spectrometry (GC-MS), which is highly specific and will definitively distinguish true amphetamine use from bupropion-related false-positives. 4, 2, 3

  3. Document the patient's complete medication history before interpreting any drug screen results, as guidelines emphasize this is essential for accurate interpretation. 4

  4. Communicate with the testing laboratory about the specific immunoassay platform being used and its known cross-reactivities, particularly when results don't correlate with clinical findings. 4

Critical Pitfalls to Avoid

Do not assume illicit drug use based solely on a positive immunoassay screen in patients taking bupropion. 4 The American Academy of Pediatrics guidelines explicitly warn that immunoassay screening tests are prone to false-positives due to cross-reactivity, and that confirmatory testing is necessary to avoid adverse consequences for patients. 4, 5

Do not discontinue bupropion or alter treatment based on an unconfirmed positive screen, as this could compromise the patient's psychiatric or smoking cessation treatment. 6

Additional Context

Other commonly prescribed medications can also cause false-positive amphetamine screens, including certain antihistamines, antidepressants, and antipsychotics. 7, 5 However, bupropion remains the single most common culprit in clinical practice. 2 The guideline literature emphasizes that drug testing cannot distinguish between appropriate medication use and substance abuse, making clinical correlation and confirmatory testing essential. 4

References

Research

Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2011

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Commonly prescribed medications and potential false-positive urine drug screens.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010

Guideline

Bupropion Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.